Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACE‐1 and GSK‐3β Inhibitors
Federica Prati(Italian Institute of Technology), Andrea Cavalli(Italian Institute of Technology), Andrea Armirotti(Italian Institute of Technology), Marco Racchi(University of Pavia), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Letizia Polito(Roche (Switzerland)), Ana Pérez‐Castillo(Instituto de Investigaciones Biomédicas Sols-Morreale), Maria Summa(Italian Institute of Technology), Paola Bisignano(Vanderbilt University), Daniela Pizzirani(Italian Institute of Technology), Rita Scarpelli(Sapienza University of Rome), María Laura Bolognesi(University of Bologna), Angela De Simone(University of Turin), Vincenza Andrisano(University of Bologna), Giovanni Bottegoni(University of Urbino), Angelo D. Favia(Italian Institute of Technology), Francesca Massenzio(Babraham Institute), Barbara Monti(University of Bologna), Daniel I. Pérez(Cedars-Sinai Medical Center)
Cited by 123
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293